Luspatercept Outperforms ESA with Durable Responses in LR-MDSLuspatercept Outperforms ESA with Durable Responses in LR-MDS
- Luspatercept outperformed epoetin alfa on every efficacy measure — initial RBC-TI rates (76% vs. 56%), sustained TI at 2.5 years (25.3% vs. 10.5%), and median response duration exceeding three years.
- Over a quarter of luspatercept-treated patients achieved long-term transfusion independence, reinforcing sustained TI — not just initial response — as the clinically meaningful benchmark in LR-MDS.
- An OS signal is emerging but not yet significant — median OS unreached in the luspatercept arm vs. 46 months with epoetin alfa, with survival curves separating in favor of luspatercept for the first time in a prospective randomized LR-MDS trial.
- Tolerability remained acceptable with long-term use, including in older patients; discontinuation due to lack of efficacy was lower with luspatercept than ESA, supporting its feasibility as frontline therapy.
Updated results from the phase 3 COMMANDS trial, presented at the 2026 ASCO Annual Meeting, provide the most comprehensive long-term look yet at luspatercept in ESA-naïve patients with lower-risk MDS. COMMANDS is a randomized, open-label trial comparing luspatercept versus epoetin alfa in patients with very low, low, or intermediate-risk MDS with transfusion dependence. The primary endpoint — RBC transfusion independence (RBC-TI) for at least 12 weeks with a concurrent hemoglobin rise of at least 1.5 g/dL — consistently favored luspatercept across all analyses.
Durable Transfusion Independence
With extended follow-up, luspatercept demonstrated superior initial RBC-TI rates (76% vs. 56%) and substantially more durable responses. At approximately 2.5 years, sustained RBC-TI remained more than twofold higher with luspatercept (25.3% vs. 10.5%), with median response durations exceeding three years in some analyses. As Dr. Guillermo Garcia-Manero, Chair of the Department of Leukemia and leader of the MDS Program at MD Anderson Cancer Center, noted, “over a quarter of the patients are long-term responders” — a clinically meaningful finding in a population where chronic anemia and transfusion burden substantially affect quality of life and healthcare utilization.
An Emerging OS Signal
Updated OS data remain immature but informative. Median OS has not been reached in the luspatercept arm, compared with 46 months in the epoetin alfa arm, with a hazard ratio favoring luspatercept that has not yet reached statistical significance. The absence of significance reflects the well-recognized challenges of demonstrating OS benefit in lower-risk MDS, where prolonged disease course, crossover, and subsequent therapies can obscure between-arm differences.
Still, the survival signal is hard to dismiss. As Dr. Garcia-Manero observed, “the survival curves really separate — and it’s quite impressive, because the median survival on the luspatercept arm has not been reached.” He framed this as a potential paradigm shift: “In the past, our main objective was to decrease the number of blood transfusions that we give to our patients. This data suggests that in doing so with a safe agent that is active, we may also be improving the survival of these patients.” For the first time in a prospective randomized study of this population, long-term follow-up shows survival curve separation favoring luspatercept — observations that remain hypothesis-generating but raise the possibility that durable correction of anemia carries broader prognostic implications than previously appreciated.
Safety and Tolerability
Safety findings are consistent with prior reports. Rates of treatment-emergent adverse events were higher with luspatercept — including an increased incidence of hypertension — but overall tolerability was acceptable. Discontinuation due to lack of efficacy was lower with luspatercept than epoetin alfa, supporting the feasibility of long-term therapy in this predominantly older population.
Clinical Implications for Practice
The updated COMMANDS data challenge ESAs as the default first-line approach in LR-MDS on several fronts: luspatercept demonstrated superior and more durable efficacy in ESA-naïve patients; sustained transfusion independence — not just initial response — emerged as a key endpoint linked to improved outcomes; and the OS signal, while not definitive, suggests that earlier use of erythroid maturation agents may favorably influence disease trajectory. For clinicians managing these patients in community settings, Dr. Garcia-Manero put it directly: “I will start thinking about this intervention through the prism of not only mitigating transfusions but also improving their survival.”
Looking Ahead
On timing, investigators are increasingly asking whether luspatercept should be initiated before patients become heavily transfusion dependent — a question the ongoing ELEMENTS trial is designed to answer.
The ASCO 2026 COMMANDS update reinforces luspatercept as a frontline option for anemia in ESA-naïve LR-MDS, with clear advantages in response rate and durability. An OS benefit remains unproven, but the consistency and magnitude of hematologic improvement — and a survival signal that is strengthening with follow-up — continue to support its expanding role in lower-risk MDS.
